Avalo is a clinical-stage biotechnology company fully dedicated to developing therapeutics targeting the IL-1β pathway for immune-mediated inflammatory diseases. Positive topline data was recently reported for our lead asset, abdakibart (AVTX-009), in a Phase 2 trial in hidradenitis suppurativa (HS). We’re also exploring additional opportunities to make an impact in prevalent indications that have significant remaining unmet needs and advancing AVTX-010, a long-acting next-generation anti-IL-1β antibody.